GW Pharmaceuticals received approval for Epidyolex®(cannabidiol) for the treatment of seizures linked to tuberous sclerosis complex (TSC) in the UK.
List view / Grid view
The European medical cannabis market lacks a common regulatory framework; Peter Kohut charts a route through the complexity and highlights opportunities for the taking.
According to Jazz Pharmaceuticals, the combined company will be a leader in neuroscience, well positioned to maximise the value of its diversified portfolio.
Ten medicines have been recommended for marketing authorisation and 10 extensions of indication have been suggested by the EMA.
Epidyolex, a cannabidiol oral solution, has been given approval by the FDA to treat seizures associated with tuberous sclerosis complex (TSC).
GW Pharmaceuticals's Epidyolex (cannabidiol) has been changed from a Schedule 2 drug to a Schedule 5 drug, making it exempt from virtually all controlled drug requirements.
Epidyolex, which contains cannabidiol, can now be prescribed by doctors to epilepsy patients in the UK through the NHS.
Following guidance from the drugs advisory body NICE, two cannabis-based medications have been approved for treatment by the NHS in England.
The cannabidiol-based treatment EPIDYOLEX has been granted marketing authorisation from the European Commission.
EMA’s human medicines committee had cleared the cannabidiol oral solution, Epidiolex, for use to treat seizures.
The FDA has approved Epidiolex oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy...